Lynparza approved in China for prostate cancer
24 June 2021 07:00 BST Lynparza approved in China for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer Only PARP inhibitor to improve overall survival versusnew hormonal treatments in advanced prostate cancer First PARP inhibitor approved in China in advanced prostate cancer AstraZeneca and MSD's Lynparza (olaparib) has been granted conditional approval in China to treat adult patients with germline or somatic BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following treatment that included a new hormonal